ABCL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abcellera Biologics Inc (ABCL) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, and the company is currently experiencing financial challenges despite significant revenue growth. While options data suggests bullish sentiment, the lack of positive catalysts, recent news, or strong trading signals makes it prudent to hold off on investing until clearer positive trends emerge.
The technical indicators for ABCL are bearish. The MACD is negatively expanding below zero, the RSI is neutral at 37.485, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 3.454, with key support at 3.303 and resistance at 3.605.
The company's revenue increased significantly in 2025/Q4, up 788.18% YoY, and gross margin remains strong at 100%.
The MACD and moving averages indicate a bearish trend, and there is no recent news or significant insider/hedge fund activity to support a positive outlook.
In 2025/Q4, revenue increased significantly to $44.85M (up 788.18% YoY), but net income dropped to -$8.95M (down -73.85% YoY), and EPS fell to -0.03 (down -75.00% YoY). Gross margin remained strong at 100%.
No recent analyst ratings or price target updates are available for ABCL.
